Emerging treatments are expected to help fill the need for safer and more effective therapies for atopic dermatitis (AD). Both systemic and topical treatments are needed to provide full and complete treatment for patients with AD. Targeting the specific axis or axes that control AD may contribute to developing personalized approaches to treatment
A digitally assisted vitreoretinal surgery system offers enhanced visualization for surgeons and observers, better ergonomics for greater surgeon comfort, and may improve patient safety by allowing use of lower endoillumination levels.
Implantation of a silicone oil-filled accommodating IOL (FluidVision, PowerVision) provides 3 to 4 D of accommodation along with excellent distance, intermediate, and near vision—all of which remain stable during follow-up to 2 years, said Louis D. Nichamin, MD.
A novel glaucoma monitoring system is being developed to guide providers in establishing personalized monitoring schedules that would help them avoid missing significant progression in glaucoma suspects or patients with open-angle glaucoma, said Joshua D. Stein, MD, MS.
Analyses of data from the OASIS study confirm the efficacy of intravitreal ocriplasmin for the treatment of symptomatic vitreomacular traction/vitreomacular adhesion (VMT/VMA) and the importance of proper patient selection, said Peter K. Kaiser, MD.
Swept-source, microscope-integrated, ocular coherence tomography (SS-MIOCT) is a new investigational technology for real-time intraoperative imaging of the cornea and anterior segment, said Terry Kim, MD.
Results from the Diabetic Retinopathy Clinical Research Network Protocol S provide evidence for the first major advance in the treatment of proliferative diabetic retinopathy (PDR) in more than 40 years, said Jeffrey Gross, MD.
SAKURA is a 24-month phase III study investigating the efficacy and safety of intravitreal sirolimus for treatment of noninfectious posterior segment uveitis. Data were reported from the primary endpoint visit at 5 months.